BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
113.08
+1.74 (1.56%)
Dec 20, 2024, 4:00 PM EST - Market closed
BioNTech SE Revenue
BioNTech SE had revenue of 1.24B EUR in the quarter ending September 30, 2024, with 39.04% growth. This brings the company's revenue in the last twelve months to 3.04B, down -54.07% year-over-year. In the year 2023, BioNTech SE had annual revenue of 3.82B, down -77.94%.
Revenue (ttm)
3.04B EUR
Revenue Growth
-54.07%
P/S Ratio
8.04
Revenue / Employee
495,695 EUR
Employees
6,133
Market Cap
27.11B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | 108.60M | -18.98M | -14.87% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cardinal Health | 224.45B |
| Centene | 146.20B |
| Humana | 115.01B |
| Koninklijke Philips | 20.12B |
| Teva Pharmaceutical | 16.77B |
| Biogen | 9.61B |
| DexCom | 3.95B |
| Mettler-Toledo International | 3.76B |
BNTX News
- 8 days ago - US FDA lifts partial clinical hold on BioNTech cancer drug study - Reuters
- 15 days ago - Why Is BioNTech Stock Trading Higher On Friday? - Benzinga
- 4 weeks ago - BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It. - Barrons
- 5 weeks ago - Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head - Investopedia
- 5 weeks ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 5 weeks ago - Pharma shares hit as Trump picks RFK Jr to lead health department - The Guardian
- 5 weeks ago - Vaccine maker stocks fall on reports Trump plans to tap RFK Jr. to lead HHS - CNBC
- 5 weeks ago - BioNTech buys China's Biotheus to support oncology strategy - Reuters